Tevogen Bio Appoints Afshin Beheshti to Advisory Board

WARREN, N.J.–(BUSINESS WIRE)–Tevogen Bio Inc. today announced the appointment of Afshin Beheshti, PhD, to Tevogen’s Advisory Board.

Dr. Beheshti joined KBR at NASA Ames Research Center in 2017 to contribute to the GeneLab genetics database project. He currently works as Blue Marble Space Institute of Science and is funded through grants to work on COVID-19, cancer research, space biology, and high-altitude human biology effects. Dr. Beheshti also is a Visiting Researcher at the Broad Institute of MIT and Harvard. He is the President of two non-profits: the COVID-19 International Research Team (COV-IRT), which is dedicated to COVID-19 and Long COVID research, and Kwaai, an organization promoting free AI access through Personal AI. Previously, Dr. Beheshti was an Assistant Professor at Tufts University School of Medicine, focusing on cancer research. Dr. Beheshti earned his Ph.D. in physics from Florida State University before transitioning to postdoctoral training in cancer, systems biology, space biology, and radiation biology.

“Tevogen’s T cell therapy platform will have applications to many different diseases that has potential to improve patient outcome and quality of life,” Dr. Beheshti shared.

“Dr. Beheshti’s remarkable blend of expertise in physics, systems biology, and space biology, coupled with his innovative work in cancer research and commitment to global health challenges like COVID-19, makes him an invaluable addition to our Advisory Board,” said Tevogen CEO, Ryan Saadi, MD, MPH.

Dr. Beheshti’s contributions have earned him recognition and accolades, including the International Space Station Research & Development Award for Compelling Results in Biology from the American Astronaut Society/NASA, the NASA Exceptional Scientific Achievement Medal, One KBR Award, and the NASA Outstanding Service Award: NASA Ames Safety Award Program II.

About Tevogen Bio

Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and twelve pending patents, two of which are related to artificial intelligence.